HDAC9 and triple-A syndrome: In mouse models of AAA, treatment with class I HDAC inhibitors (MS-275) or class IIa (MC-1568) reduced the incidence of AAA, the inflammatory phenotype of macrophages, and the concentration of pro-inflammatory mediators [85].